KEY DETAILS
California now requires stricter privacy rules for GLP-1 prescriptions linked to weight loss or body image.
New York is requiring insurance companies to choose between owning an insurer and owning a pharmacy middleman, not both.
JMT206, a new GLP-1 drug, is entering its first human safety trial in 90 obese participants starting late 2026.
A Chinese drugmaker is testing mazdutide, a new GLP-1 drug, in 240 people with type 2 diabetes starting October 2026.
On Tuesday, September 29, 2026, four developments moved GLP-1 access forward across two fronts: state oversight and new drug research. New York and California both tightened rules around GLP-1 prescriptions, though from different angles: one aimed at pricing conflicts, the other at privacy. Meanwhile, two new GLP-1 drug candidates entered testing that could expand treatment options in the coming years. Together, these changes touch how patients are protected today and what may be available tomorrow.
California's updated rule recognizes that GLP-1 prescriptions often carry more than a diagnosis code. When a prescription is linked to weight loss or body image, it can reveal something the patient may want kept private, from family members to employers to anyone with informal access to health records. The new privacy requirements apply an extra layer of confidentiality to this kind of sensitive health data. For patients using these medications, that means their prescription history should be handled with the same discretion as other sensitive personal medical information. Anyone filling a GLP-1 prescription in California may want to ask their pharmacy or provider how these new safeguards affect what gets shared and with whom.
New York's proposal responds to a structural conflict that has drawn increasing scrutiny nationwide. When one company owns both an insurance plan and the pharmacy benefit manager that negotiates drug prices, it controls both what a patient pays and what the middleman earns from that transaction. Lawmakers argue this overlap gives companies an incentive to steer patients toward more expensive drugs or block cheaper alternatives, since the same business benefits either way. By requiring insurers to choose one role or the other, New York aims to remove that incentive and create clearer accountability for GLP-1 pricing. If the bill passes, it could change how insurers in the state structure their pharmacy benefit contracts going forward.
JMT206 is now moving into its first clinical test in humans, a Phase 1 safety trial designed to check how the drug is tolerated at different doses. The trial will enroll 90 participants with obesity, starting in late 2026, and will focus on safety rather than effectiveness at this early stage. Phase 1 trials like this one are the first step in a long process, and most candidate drugs still have years of testing ahead before they might reach patients. Still, each new GLP-1 candidate entering trials adds to the pool of treatments in development, which may eventually offer patients more options.
Mazdutide is entering a Phase 2 trial focused specifically on people with type 2 diabetes, a later stage of testing than JMT206's current trial. The study will enroll 240 participants starting in October 2026, and Phase 2 trials typically look at both safety and how well a drug works, which gives researchers an early read on effectiveness before moving to larger trials. Because mazdutide is being developed by a Chinese pharmaceutical company, its progress may also signal how international drug development is expanding the range of GLP-1 options beyond currently available brands. Patients with type 2 diabetes watching new drug development may want to track this trial as it moves toward results, though any wider availability remains several years away.
Taken together, these developments show regulators and drug makers working on different timelines but toward the same goal: making GLP-1 treatment safer, fairer, and more available. Patients in New York and California may want to follow how their state's rules affect their coverage and privacy, while anyone considering future GLP-1 options can keep an eye on how JMT206 and mazdutide progress through trials. None of these changes are final yet, and each will take time to unfold. The most useful step for readers right now is to stay informed about their own state's rules and to talk with their care team about how new developments might affect their treatment.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.